Suven Life Sciences Ltd
NSE: SUVEN · Healthcare Research, Analytics & Technology · sector
₹262.00NSE close 2026-10-26
Key numbers
Market cap₹6,917 cr
Price₹262.00
52w high / low₹403 / ₹124
P/E–Sector median 27.9x
P/B11.7xSector median 3.0x
Book value₹22.4
Dividend yield–Sector median 0.34%
ROE-100.5%Sector median 6.1%
ROCE-59.5%Sector median 9.8%
OPM-4,155.5%Sector median 8.4%
Debt / equity0.00xSector median 0.01x
EV/EBITDA–Sector median 14.8x
Interest cover-555.0x
Current ratio17.69x
Sales growth 3y-19.3%Sector median +7.2%
Profit growth 3y–Sector median -13.6%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 9 companies in Healthcare Research, Analytics & Technology (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹337 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest -555.0x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding fell by 1.89 percentage points in a year, to 65.47% (2026-09-30).
- Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY23, FY22).
- Net loss in 8 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Debtor days went from 40 (FY24) to 77 (FY26).
- No dividend in the last 5 financial years.
- Price ₹262.00 on 2026-10-26: -35.0% from the 52-week high, +111.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹372.85 · low ₹107.21
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| EBITDA | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 |
| OPM % | -2,031.5% | -2,435.4% | -2,981.0% | -2,713.9% | -8,670.7% | -3,677.9% | -3,330.9% | -3,711.5% |
| Other income | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Net profit | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| EPS (₹) | -2.27 | -1.79 | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 | -4.84 |
| Revenue YoY | -64.2% | +74.5% | +3.4% | +90.9% | ||||
| Profit YoY | – | – | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 12 | 14 | 12 | 7 | 7 | 9 |
| EBITDA | -122 | -120 | -121 | -166 | -284 | -366 |
| Net profit | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS (₹) | -9.57 | -6.63 | -4.82 | -7.37 | -12.13 | -14.89 |
| Revenue growth | +14.4% | -13.7% | -43.0% | +6.8% | +17.3% | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -19.3% | -12.0% | +17.3% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | +50.4% (2y) | +41.1% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 375 | 270 | 110 | 591 |
| Borrowings | – | 0 | 0 | 0 | 0 |
| Cash & equivalents | – | 231 | 240 | 60 | 337 |
| Total assets | – | 389 | 285 | 135 | 624 |
| Fixed assets | – | 36 | 28 | 59 | 56 |
| Capital work in progress | – | 0 | 0 | 0 | 4 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 1 | 1 | 1 | 2 |
| Inventory | – | 0 | 1 | 0 | 0 |
| Payables | – | 2 | 2 | 5 | 5 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -128 | -208 | -83 | -154 | -302 |
| Cash from investing | -22 | -156 | 62 | 155 | -462 |
| Cash from financing | 146 | 396 | -1 | -1 | 757 |
| Capex | 20 | 3 | 2 | 37 | 5 |
| Free cash flow | -147 | -211 | -85 | -191 | -307 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -31.5% | -38.9% | -146.1% | -46.7% |
| ROCE % | – | -31.4% | -39.2% | -146.1% | -46.7% |
| Debtor days | – | 22 | 40 | 73 | 77 |
| Inventory days | – | 0 | 22 | 13 | 5 |
| Payable days | – | 45 | 65 | 287 | 247 |
| Cash conversion cycle (days) | – | -23 | -3 | -201 | -165 |
| Working capital days | – | 6,482 | 7,590 | 2,851 | 26,462 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 65.47% |
| FIIs | 0.46% |
| DIIs | 2.17% |
| of which Mutual funds | 0.08% |
| Public (non-institutions) | 31.90% |
| Quarter | Jul 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | Jul 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 67.43% | 67.36% | 67.36% | 70.15% | 70.15% | 70.08% | 65.47% | 65.47% |
| Promoter group | % |
|---|---|
| JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its Capacity as sole trustee of Jasti Family Trust) | 64.93% |
| Sudharani Jasti | 0.54% |
| Venkateswarlu Jasti | 0.00% |
| Kalyani Jasti | 0.00% |
| Sirisha Jasti | 0.00% |
| Madhavi Jasti | 0.00% |
| Public holders above 1% | % |
|---|---|
| Tejas Trivedi | 1.34% |
| Ketan C Sheth | 1.21% |
67,431 shareholders. Pledged: 0.00% of promoter shares.
Peers in Healthcare Research, Analytics & Technology
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹14,527 cr | 65.4x | 3.0x | 4.6% | 7.0% | 19.8% | +5.4% | 0.35% |
| INDGN | ₹14,472 cr | 36.0x | 4.6x | 13.9% | 17.4% | 16.2% | – | 0.33% |
| SUVEN | ₹6,917 cr | – | 11.7x | -100.5% | -59.5% | -4,155.5% | -19.3% | – |
| VIMTALABS | ₹2,185 cr | 27.4x | 4.8x | 19.1% | 23.5% | 34.3% | +8.9% | 0.20% |
| BI | ₹189 cr | 4.3x | 1.0x | 2.3% | 7.0% | 8.4% | +274.4% | – |
| TAKE | ₹154 cr | 12.1x | 5.0x | 49.8% | 20.1% | -2.0% | -34.1% | – |
| NOVELIX | ₹141 cr | 31.7x | 3.0x | 11.3% | 8.8% | 3.1% | +411.3% | – |
| JSTL | ₹102 cr | 28.5x | 1.4x | 6.1% | 9.8% | 20.5% | +19.4% | 0.97% |
| ADESHWAR | ₹23 cr | 18.0x | 0.9x | 5.5% | 10.2% | 4.9% | -12.0% | – |
All 9 companies in Healthcare Research, Analytics & Technology →
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-07-30 | Other | Annual General Meeting |
| 2023-08-02 | Other | Annual General Meeting |
| 2022-10-17 | Rights | Rights 1:2 @ Premium Rs 54/- |
| 2022-07-29 | Other | Annual General Meeting |
| 2021-08-02 | Other | Annual General Meeting |
| 2020-09-11 | Other | Annual General Meeting |
| 2020-01-21 | Restructuring | Demerger |
| 2019-08-08 | Other | Annual General Meeting |
| 2019-02-14 | Dividend | Interim Dividend - Rs 1.50 Per Share |
| 2018-08-09 | Other | Annual General Meeting |
| 2018-02-06 | Dividend | Interim Dividend - Rs 1.50 Per Share (Purpose Revised) |
| 2017-08-09 | Other | Annual General Meeting |
| 2017-02-08 | Dividend | Interim Dividend Re 1 Per Share |
| 2016-08-04 | Other | Annual General Meeting |
| 2016-03-14 | Dividend | Interim Dividend - Re 1/- Per Share / Special Dividend - Re 1/- Per Share (Purpose Revised) |
| 2015-07-23 | Dividend | Annual General Meeting/Dividend - Re 0.60/- Per Share |
| 2014-07-24 | Dividend | Annual General Meeting /Final Dividend - Re 0.50/- Per Share + Special Dividend - Rs 2/- Per Share |
| 2013-08-01 | Dividend | Annual General Meeting / Dividend - Re.0.30/- Per Equity Share |
| 2012-09-17 | Dividend | Annual General Meeting And Dividend Re.0.30 Per Share |
| 2011-08-01 | Dividend | Annual General Meeting And Dividend Re.0.25 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Professional, scientific and technical: Scientific research and development
| Sector | Healthcare |
| Industry | Healthcare Research, Analytics & Technology |
| Sub-industry | Healthcare Research, Analytics & Technology |
| Symbol | SUVEN |
| BSE code | 530239 |
| ISIN | INE495B01038 |
| Face value | ₹1.0 |
| Incorporated | 1989-03-09 |
| Website | www.suven.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.